Evaluation of Impact of Statin Use on Development of CPK Elevation During Daptomycin Therapy

Annals of Pharmacotherapy

Volumn 48, Issue 3, 2014, Pages 320-327

  Berg, Melody L ^a   Estes, Lynn L ^a   Dierkhising, Ross A ^a   Curran, Brian ^a   Enzler, Mark J ^a  

^a MAYO CLINIC   (United States)

Author keywords

adverse drug reaction; creatine phosphokinase; daptomycin; drug interaction; drug safety; HMG Co A reductase inhibitors

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CREATININE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; MYOPATHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; YOUNG ADULT;

ADVERSE DRUG REACTION; CREATINE PHOSPHOKINASE; DAPTOMYCIN; DRUG INTERACTION; DRUG SAFETY; HMG CO-A REDUCTASE INHIBITORS;

AGED; ANTI-BACTERIAL AGENTS; CREATINE KINASE; DAPTOMYCIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK;

EID: 84896860480     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013514377     Document Type: Article

References (24)

1. Edwards C,King K,Garcia R.Early onset rhabdomyolysis associated with daptomycin.Infect Dis Clin Pract. 2006;14:327-328.
2. Papadapolous S,Ball A,Liewer S,Martin C,Winstead P,Murphy B.Rhabdomyolysis during therapy with daptomycin.Clin Infect Dis. 2006;42:e108-e110.
3. Patel S,Samo T,Suki W.Early-onset rhabdomyolysis related to daptomycin use.Int J Antimicrob Agents. 2007;30:472-474.
4. Lexington, MA: Cubist Pharmaceuticals; 2008:.
5. Figueroa D,Mangini E,Amodio-Groton M,Vardianos B,Melchert A,Fana C.Safety of high dose intravenous daptomycin treatment: three year cumulative experience in a clinical trial program.Clin Infect Dis. 2009;49:177-180.
6. Kullar R,Davis S,Levine D,et al.High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study.Pharmacotherapy. 2011;31:527-536.
7. Odero R,Cleveland K,Gelfand M.Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG coA reductase inhibitor.J Antimicrob Chemother. 2009;63:1299-1300.
8. Blanco M,Nombela F,Castellanos M,et al.Statin treatment withdrawal in ischemic stroke: a controlled-randomized study.Neurology. 2007;69:904-910.
9. Endrichs M,Laufs U.Discontinuation of statin treatment in stroke patients.Stroke. 2006;37:2640-2643.
10. Rashtchizadeh N,Argani H,Ghorbanihaghjo A,Nezami N,Safa J,Montazer-Saheb S.C reactive protein level following treatment and withdrawal of lovastatin in diabetic neuropathy.Iran J Kidney Dis. 2009;3:93-98.
11. Risselada R,Straatman H,van Kooten F,et al.Withdrawal of statins and risk of subarrachnoid hemorrhage.Stroke. 2009;40:2887-2892.
12. Spencer F,Fonarow G,Frederick P,et al.Early withdrawal of statin therapy in patients with non-st-segment elevation myocardial infarction: National Registry of Myocardial Infarction.Arch Intern Med. 2004;164:2162-2168.
13. Spencer FA,Allegrone J,Goldberg RJ,et al.Association of statin therapy with outcomes of acute coronary syndromes: The GRACE Study.Ann Intern Med. 2004;140:857-866.
14. Sposito AC,Carvalho LSF,Cintra RMR,et al.Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal.Atherosclerosis. 2009;207:191-194.
15. Huerta-Alardin AL,Varon J,Marik PE.Bench-to-bedside review: rhabdomyolysis-an overview for clinicians.Crit Care. 2004;9:158-169.
16. Melli G,Chaudhry V,Cornblath DR.Rhabdomyolysis: an evaluation of 475 hospitalized patients.Medicine. 2005;84:377-385.
17. Zhou SF.Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.Curr Drug Metab. 2008;9:310-322.
18. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury (June9, 2011). http://www.fda.gov/drugs/drugsafety/ucm256581.htm. 2011.
19. Parra-Ruiz J,Dueñas-Guitérrez C,Tomás-Jiménez C,Linares-Palomino J,Garrido-Gomez J,Hernández-Quero J.Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy.Eur J Clin Microbiol Infect Dis. 2001;8:1771-1774.
20. Golightly LK,Barber GR,Barron MA,Page RL.Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.Drug Metabol Drug Interact. 2013;28:49-58.
21. Bhavani S,Rubino C,Ambrose P,Drusano G.Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.Clin Infect Dis. 2012;50:1568-1574.
22. Gurevich VS,Shovman O,Slutzky L,Meroni PL,Shoenfeld Y.Statins and autoimmune disease.Autoimmun Rev. 2005;4:123-129.
23. Liao JK,Laufs U.Pleiotropic effects of statins.Annu Rev Pharmacol Toxicol. 2005;45:89-118.
24. Harris P,Taylor R,Thielke R,Payne J,Gonzalez N,Conde J.Research electronic data capture (REDcap): a metadata-driven methodology and workflow process for providing translational research informatics support.J Biomed Inform. 2009;42:377-381.